RTN3: A Potential Drug Target and Biomarker (G10313)
RTN3: A Potential Drug Target and Biomarker
RTN3 (Reticulon-3) is a protein that is expressed in various tissues and cells of the human body. It is a member of the retinoic acid receptor (RAR) family, which is a well-established gene family that plays a crucial role in the development and maintenance of tissues with specific functions, such as eyes, hair, and nails. The RAR family also includes the RXR gene, which encodes for the retinoblastoma gene (RB).
While RTN3 has been identified as a potential drug target and biomarker, more research is needed to fully understand its role in the body and its potential as a therapeutic agent.
The RAR family of proteins is involved in the regulation of gene expression and cell signaling. The RAR proteins function by binding to specific DNA sequences and regulating the activity of various transcription factors. These transcription factors are responsible for transmitting genetic information from the DNA to the ribosome, which then synthesizes proteins. By binding to specific DNA sequences, the RAR proteins can either activate or inhibit the activity of these transcription factors.
RTN3 is a 21-kDa protein that is expressed in various tissues and cells of the body. It is highly conserved, with a calculated identity of 97% at the amino acid level and a calculated fold of 1.5 angstroms. RTN3 is involved in the regulation of gene expression and cell signaling, and is thought to play a role in the development and maintenance of tissues with specific functions, such as eyes, hair, and nails.
One of the key functions of RTN3 is its role in the regulation of cell signaling. It is involved in the development and maintenance of tissues with specific functions, such as the development of hair and nails, and is thought to play a role in the regulation of cell signaling pathways that are involved in the development and maintenance of these tissues.
In addition to its role in cell signaling, RTN3 is also involved in the regulation of gene expression. It is a strong predictor of gene expression, and has been shown to play a role in the regulation of gene expression in various tissues and cells of the body.
The potential drug target status of RTN3 is supported by several studies. First, several studies have shown that RTN3 is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Second, several studies have shown that inhibition of RTN3 has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.
Finally, several studies have shown that RTN3 is a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The levels of RTN3 have been shown to be elevated in various tissues and cells of the body, and have been used as a diagnostic marker for these diseases.
In conclusion, RTN3 is a protein that is involved in the regulation of gene expression and cell signaling, and is thought to play a role in the development and maintenance of tissues with specific functions, such as eyes, hair, and nails. Its potential as a drug target and biomarker is supported by several studies, and further research is needed to fully understand its role in the body.
Protein Name: Reticulon 3
Functions: May be involved in membrane trafficking in the early secretory pathway. Inhibits BACE1 activity and amyloid precursor protein processing. May induce caspase-8 cascade and apoptosis. May favor BCL2 translocation to the mitochondria upon endoplasmic reticulum stress. Induces the formation of endoplasmic reticulum tubules (PubMed:25612671). Also acts as an inflammation-resolving regulator by interacting with both TRIM25 and RIGI, subsequently impairing RIGI 'Lys-63'-linked polyubiquitination leading to IRF3 and NF-kappa-B inhibition
The "RTN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTN3 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
RTN4 | RTN4IP1 | RTN4R | RTN4RL1 | RTN4RL2 | RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4 | S1PR5 | SAA1 | SAA2 | SAA2-SAA4 | SAA3P | SAA4 | SAAL1 | SAC3D1 | SACM1L | SACS | SACS-AS1 | SAE1 | SAFB
